Literature DB >> 7640629

Role of platelets and complement in the clearance of epimastigote forms of Trypanosoma cruzi.

L F Umekita1, R M Piazza, I Mota.   

Abstract

1. Trypanosoma cruzi epimastigote forms are very rapidly removed from the circulation of normal and C5-deficient mice. Depletion of C3 by cobra venom factor results in a significant delay in parasite clearance. 2. During parasite clearance there is a significant decrease in the number of circulating platelets and parasite clearance is considerably delayed in thrombocytopenic animals. 3. In vitro incubation of epimastigote forms with normal mouse serum leads to the formation of parasite clumps provided that platelets are present. Inactivation of factor B or depletion of C3 prevents this phenomenon. 4. When epimastigotes are incubated with normal mouse serum they absorb one or more factors required for their aggregation with platelets. 5. It is suggested that in mice T. cruzi epimastigote forms are removed from circulation by the alternative pathway of complement activation and that both C3 and platelets are required for parasite clearance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7640629

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  2 in total

Review 1.  Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on host-pathogen interactions.

Authors:  Fiona M Sansom; Simon C Robson; Elizabeth L Hartland
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

2.  Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection.

Authors:  Anthony W Ashton; Shankar Mukherjee; F N U Nagajyothi; Huan Huang; Vicki L Braunstein; Mahalia S Desruisseaux; Stephen M Factor; Lillie Lopez; Joan W Berman; Murray Wittner; Philipp E Scherer; Valerie Capra; Thomas M Coffman; Charles N Serhan; Katherine Gotlinger; Kenneth K Wu; Louis M Weiss; Herbert B Tanowitz
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.